Gestational diabetes & diabetes in pregnancy
Metformin and small for gestational age babies: findings of a randomised placebo-controlled clinical trial of metformin in gestational diabetes (EMERGE)
Authors' conclusion
Pre-eclampsia was strongly associated with SGA infants. Metformin-exposed SGA infants did not display a more severe SGA phenotype than infants treated with placebo.
Study context
- Population
- Women with gestational diabetes mellitus (GDM) in the EMERGE trial with a live-born infant and known infant birthweight and gestational age at delivery
- Comparison
- Metformin vs placebo; Small for gestational age (SGA) vs non-SGA pregnancies
- Primary endpoint
- Risk factors for SGA infants, incl. effect of metformin exposure on SGA status
Methodological detailsprespecified secondary analysis, placebo-controlled
- Prespecified secondary analysis
- Placebo-controlled
Primary result
As reported in the abstract
Risk factors for SGA
Pre-eclampsia, SGA vs non-SGA
18.2% vs 2.0%
p=0.001
Gestational hypertension, SGA vs non-SGA
22.7% vs 5.4%
p=0.005
Further findings
Perinatal outcomes among SGA pregnancies · Preterm birth
P = 1.00
Perinatal outcomes among SGA pregnancies · Caesarean delivery
P = 0.25
Perinatal outcomes among SGA pregnancies · Neonatal care unit admission
P = 0.27
Perinatal outcomes among SGA pregnancies
- Preterm birth, Caesarean delivery and neonatal care unit admission did not differ between metformin and placebo
Original publication
Metformin and small for gestational age babies: findings of a randomised placebo-controlled clinical trial of metformin in gestational diabetes (EMERGE). Diabetologia. Published 31 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →